000 02162 a2200649 4500
005 20250517184954.0
264 0 _c20181015
008 201810s 0 0 eng d
022 _a1365-2893
024 7 _a10.1111/jvh.12801
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBrown, A
245 0 0 _aEfficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
_h[electronic resource]
260 _bJournal of viral hepatitis
_c05 2018
300 _a457-464 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650 0 4 _aAdolescent
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aAmides
650 0 4 _aAntiviral Agents
_xadministration & dosage
650 0 4 _aBenzofurans
_xadministration & dosage
650 0 4 _aCarbamates
650 0 4 _aCyclopropanes
650 0 4 _aDrug Therapy, Combination
_xadverse effects
650 0 4 _aDrug-Related Side Effects and Adverse Reactions
_xepidemiology
650 0 4 _aFemale
650 0 4 _aGenotype
650 0 4 _aHepacivirus
_xclassification
650 0 4 _aHepatitis C, Chronic
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aImidazoles
_xadministration & dosage
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aQuinoxalines
_xadministration & dosage
650 0 4 _aRibavirin
_xadministration & dosage
650 0 4 _aSulfonamides
650 0 4 _aSustained Virologic Response
650 0 4 _aTreatment Outcome
650 0 4 _aYoung Adult
700 1 _aHézode, C
700 1 _aZuckerman, E
700 1 _aFoster, G R
700 1 _aZekry, A
700 1 _aRoberts, S K
700 1 _aLahser, F
700 1 _aDurkan, C
700 1 _aBadshah, C
700 1 _aZhang, B
700 1 _aRobertson, M
700 1 _aWahl, J
700 1 _aBarr, E
700 1 _aHaber, B
773 0 _tJournal of viral hepatitis
_gvol. 25
_gno. 5
_gp. 457-464
856 4 0 _uhttps://doi.org/10.1111/jvh.12801
_zAvailable from publisher's website
999 _c27802906
_d27802906